From August 2015 Journal of Urology: Study by New York University in which images from mpMRI identified prostate cancer before radical prostatectomy. The pathologists then took the gland and did step-sections to pinpoint the actual tumor. They found that a 9 mm “halo” of treatment around the imaged tumor boundaries would have covered 100% of the cancers. Not 80%, not 90%, but 100%.
The criticism of focal therapy has been the concern that the mpMRI images did not designate the entire tumor, thereby risking leaving some of the tumor untreated if only the imaged area was treated with HIFU. Since HIFU treats in 3 mm shots, adding 3 shots around the imaged tumor boundaries should cover the entire lesion.
Focal HIFU therapy spares non-cancerous prostate tissue, and the incidence of side effects (ED, Incontinence, Scar Tissue) was no different from “sham” operation in a study from University Central London. The 5 year cancer free statistics were excellent. The concept of focal therapy is foreign to physicians who only offer surgery or radiation, but in appropriate patients, it is a very attractive choice. A mpMRI is mandatory to ascertain significant lesions are not missed, and not all communities have facilities for this study.
High Intensity Focused Ultrasound (HIFU) Therapy is Gaining International Acceptance for the Treatment of Medical Conditions
A growing number of international medical organizations have already adopted High Intensity Focused Ultrasound (HIFU) therapy for treating an increasing number of conditions, and as a viable option to traditional invasive surgery, according to Dr. Michael Lazar, a Santa Rosa, California-based Urologist and a leading advocate for HIFU as an effective treatment for prostate cancer.
Dr. Lazar states, “The scientific community has known for years that high heat kills cancer. But only in recent years has the science advanced to the point where focused ultrasound energy can be used to provide pinpoint accuracy, sparing healthy tissue and preserving nerves, urine flow and erectile function in a majority of cases compared with traditional procedures, while also delivering the required amount of heat needed to destroy, or ablate, cancer.”
Today HIFU is being deployed around the world, especially in Europe, for the treatment of abdominal kidney tumors, urological cancers, uterine fibroids, and to relieve neuropathic pain associated with bone cancer, in addition to being a non-invasive treatment for prostate cancer. Medical literature also reports the use of HIFU in treating liver, breast and brain tumors as well as other conditions.”
For example, according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) located in Vienna, Austria, positive results were achieved with transcranial Magnetic Resonance MR-guided focused ultrasound surgery (tcMRgFUS) as a non-invasive treatment of essential tremors, neuropathic pain and Parkinson’s disease. CIRSE also reports that there have also been some investigations into the use of HIFU for temporarily opening the blood-brain barrier, allowing absorption of drugs into the brain.
Furthermore, a minimally invasive catheter-based HIFU system — designed to ablate heart tissue responsible for atrial fibrillation — has been approved for use in Europe and is undergoing an FDA approved trial in the United States.
“Adoption of HIFU has proceeded at a faster rate among international medical communities than in the United States, however, there are hopeful signs that this technique will soon be available to a broader range of patients here at home so they will not have to travel to hospitals outside of the U.S. to take advantage of this procedure,” Dr. Lazar said.
For more information about Dr. Michael Lazar, go to the HIFU website or call (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, in Santa Rosa, CA 95405.
Indianapolis, Indiana-based SonaCare Medical LLC, a leading developer of minimally-invasive HIFU technology, is bringing several HIFU systems to market to meet growing global demand. SonaCare Medical, LLC, serves customers around the world through its family of affiliate companies including: USHIFU, International HIFU and Focus Surgery. For additional information, go to: www.sonacaremedical.com.
Get a Checkup, Have a PSA Blood Test and Learn About Symptoms of the Disease as well as Treatment Options
September is national Prostate Cancer Awareness Month. About 220,800 new cases of this type of cancer are reported each year, along with 27,540 deaths attributed to the disease annually. One in seven men will be diagnosed with prostate cancer during their lifetime. While only one man in 10,000 will typically get prostate cancer under age 40, the risk increases to six of every 10 men by age 65, according to the American Cancer Society.
Prostate cancer is the second leading cause of death following lung cancer, and about one man in 38 will die of the disease. However, statistics show that most men diagnosed with the prostate cancer do not die from it, and more than 2.9 million men in the U.S. who were found to have this cancer are alive today. But why take a chance? A simple screening involving an annual blood test to measure PSA levels gives doctors a way to assess the presence and pace of the disease and the need for ongoing monitoring, a biopsy or direct intervention.
“Why is there such a difference between cancers? Some prostate cancer is very aggressive and progresses quickly, while other forms take many years to become life threatening,” said Michael Lazar, a noted urologist with a practice in Santa Rosa, California and a leading proponent of non-invasive High Intensity Focused Ultrasound (HIFU) therapy for prostate cancer treatment.
You have a number of options if it is determined that you have this disease. These include traditional surgery to remove the prostate gland, radiation (including inserting irradiated pellets into the prostate), cryotherapy (freezing of the prostate), or non-invasive HIFU therapy using sound waves to pinpoint cancer cells and destroy them without damage to surrounding healthy tissue and minimal blood loss.
Side effects associated with invasive surgical procedures including a hospital stay, a longer recovery period plus scaring, adhesions and blood loss. There is also the risk of incontinence, erectile dysfunction (ED) and a decline of libido. Radiation can ionize otherwise healthy cells that can turn into cancer latter in life. With cryotherapy, side effects include 90% to 100% ED and urethral tissue scaring that can obstruct voiding. The HIFU procedure is virtually painless, takes only a few hours, and there are fewer side effects, thereby maintaining the quality of life. Most patients are up and around the same day.
In most instances, there are no significant symptoms during the early stages of prostate cancer, and symptoms may vary from one man to another, or can be caused by other conditions. However, there are some urinary symptoms that could signal cancer including: pain or a burning sensation while urinating as well as difficulty in starting or stopping, frequent urges to go during the night, an uncontrollable bladder, a decreased flow of the urine stream, or blood in the urine. Other symptoms include painful ejaculation or difficulty in getting an erection, swelling in the legs or pelvic area, pain or numbness in the feet, legs or hips, constant bone pain leading to fractures and blood in the semen.
“My advice to every man is to obtain a baseline PSA after age 40, then yearly exams and PSA tests after 50 years of age. For those having to make a treatment choice for prostate cancer, consider all options including HIFU. While not currently available in the U.S., HIFU is pending FDA approval and is available internationally at a full-service hospital in Puerto Vallarta, Mexico, where dozens of successful HIFU procedures have been performed by me and my highly trained team,” Dr. Lazar said.
For additional information, go to the website at www.californiahifu.com, or contact Dr. Michael Lazar’s office at (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, Santa Rosa, CA 95405.